Zeltia announces results for the first half of 2014 with net sales increased by 10% and EBITDA by 12% Revenue growth (78.2 million euro, +10%) is attributable to rising sales of Yondelis® (+11%) and improved performance of Consumer Chemicals business (+10%).

EBITDA amounted to 22 million euro (+12%), despite the increase in R&D expenditure, mainly attributable to the Phase III trial with Aplidin.

Net attributable profit amounted to 16.8 million euro (+16%).

Madrid, 29 July 2014: Zeltia (Grupo Zeltia, ZEL.MC) announces its financial and corporate results for the first half of 2014. Zeltia's net sales amounted to 78.2 million euro in 1H14, up 10% with respect to the same period last year. Both of the group's main business areas - Biopharmaceuticals and Consumer chemicals - attained double-digit growth in revenues. The biopharmaceutical business obtained net sales of 41.7 million euro (+10%), of which 38 million euro correspond to Yondelis® sales, which increased by 11% compared with 1H13. The Consumer Chemicals division reported sales of 36.1 million euro (+10%), in line with the improvement observed in the first quarter of 2014.
Grupo Zeltia's EBITDA amounted to 22.1 million euro in 1H14, a 12% increase with respect to the same period last year. The oncology area was the main contributor to this performance, accounting for 24 million euro (22.5 million euro in 1H13). EBITDA increased notably despite the increase in R&D spending (+9.8%), attributable mainly to the pivotal Phase III trial with Aplidin in multiple myeloma.

Grupo Zeltia's attributable net profit amounted to 16.7 million euro in 1H14, compared with 14.4 million euro in 1H13 (+16%).
The group's net interest-bearing debt improved compared to 2013 year-end, due to the 6.6 million euro increase (+9%) in the cash position to a total of 36.2 million euro.

About Zeltia

Zeltia S.A. is a world-leading biopharmaceutical company specialised in the development of marine- based drugs for use in oncology. Grupo Zeltia consists mainly of the following companies: PharmaMar, the world-leading biotechnology company in advancing cancer care through the discovery and development of innovative marine-derived medicines; Genómica, Spain's leading molecular diagnostics company; Sylentis, dedicated to researching therapeutic applications of gene silencing (RNAi); and a chemical division comprising Zelnova and Xylazel, two highly profitable companies that are leaders in their respective market segments.

For more information +34 91 444 4500

The full financial report for the first half of 2014 could be found under the
Shareholders and investors section of Zeltia website www.zeltia.com

distributed by